Outset Medical (Outset Medical) ROCE % : -54.69% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Outset Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Outset Medical's annualized ROCE % for the quarter that ended in Dec. 2023 was -54.69%.

Outset Medical ROCE % Historical Data

The historical data trend for Outset Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outset Medical ROCE % Chart

Outset Medical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-62.65

-55.09

-33.39

-41.87

-52.62

Outset Medical Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-47.31	-49.01	-54.05	-63.51	-54.69

Outset Medical ROCE % Calculation

Outset Medical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-159.599	/	( ( (400.115 - 51.949)	+	(313.801 - 55.323) )	/ 2 )
	=	-159.599	/	( (348.166	+	258.478)	/ 2 )
	=	-159.599	/	303.322
	=	-52.62 %

Outset Medical's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-140.284	/	( ( (307.551 - 53.024)	+	(313.801 - 55.323) )	/ 2 )
	=	-140.284	/	( ( 254.527	+	258.478 )	/ 2 )
	=	-140.284	/	256.5025
	=	-54.69 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Outset Medical (NAS:OM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Outset Medical ROCE % Related Terms

Thank you for viewing the detailed overview of Outset Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Outset Medical (Outset Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Outset Medical Inc (NAS:OM) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3052 Orchard Drive, San Jose, CA, USA, 95134

Website

https://www.outsetmedical.com

Outset Medical Inc is a medical technology company. It has developed a machine, Tablo, which reduces the cost and complexity of dialysis. Tablo provides Renal Replacement Therapy in Hospitals, Chronic Care in Dialysis Clinics and Home Dialysis.

Executives

Leslie Trigg	director, officer: President & CEO	C/O OUTSET MEDICAL, 1830 BERING ROAD, SAN JOSE CA 95112
Marc Nash	officer: SVP, Operations and R&D	3052 ORCHARD DRIVE, SAN JOSE CA 95134
Jean-olivier Racine	officer: Chief Technology Officer	3052 ORCHARD DRIVE, SAN JOSE CA 95134
Nabeel Ahmed	officer: Interim CFO	3052 ORCHARD DRIVE, SAN JOSE CA 95134
Stacey L. Porter	officer: Chief People Officer	3052 ORCHARD DRIVE, SAN JOSE CA 95134
John L. Brottem	officer: General Counsel	3052 ORCHARD DR., SAN JOSE CA 95134
Steven S. Williamson	officer: Chief Commercial Officer	C/O HOLOGIC, INC., BEDFORD MA 01730
Martin Vazquez	officer: Chief Operating Officer	3052 ORCHARD DR., SAN JOSE CA 95134
James F. Hinrichs	director	3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Dale E Jones	director	C/O HUGHES SUPPLY INC, 20 N ORANGE AVE, ORLANDO FL 32801
D Keith Grossman	director
Rebecca Chambers	officer: Chief Financial Officer	3052 ORCHARD DR., SAN JOSE CA 95134
Catherine M. Szyman	director	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Warburg Pincus Llc	director, 10 percent owner	450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus X, L.p.	director, 10 percent owner	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017